B.R.A.I.N. Biotechnology Research and Information Network (BNN) AI Stock Analysis

• Market Cap: €49.81M
• Dividend Yield: N/A
• Average Volume (3M): 10.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -4.90%
• EPS Growth: -69.80%
• Country: DE
• Employees: 296
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 21,847,494
• 10 Day Avg. Volume: 22,707
• 30 Day Avg. Volume: 10,926
• PEG Ratio: -0.12
• Price to Book (P/B): 3.67
• Price to Sales (P/S): 0.85
• P/FCF Ratio: -8.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: €2.00 ▼(-35.90% Downside)

The overall stock score is primarily impacted by financial performance challenges, including persistent net losses and negative cash flows. Technical analysis suggests a neutral trend, while valuation is weak due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Business Model Strength

Diversified revenue streams from consultancy, subscriptions, and licensing provide resilience and stability, supporting long-term growth.

Strategic Partnerships

Strategic partnerships enhance innovation and financial stability through joint projects, contributing to sustained competitive advantage.

Debt Management Improvement

Improved debt management reduces financial risk and enhances the company's ability to invest in growth opportunities.

Negative Factors

Persistent Net Losses

Ongoing net losses and declining margins indicate operational inefficiencies, challenging long-term profitability and sustainability.

Negative Cash Flow

Negative cash flow from operations limits financial flexibility and may hinder the company's ability to fund future growth initiatives.

Low Equity Ratio

A low equity ratio suggests financial instability, increasing vulnerability to economic downturns and limiting investment capacity.

B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model

Company Description

B.R.A.I.N. Biotechnology Research and Information Network (BNN) is a leading organization in the biotechnology sector, dedicated to advancing research and development in genetic engineering, pharmaceuticals, and agricultural biotechnology. The company focuses on providing innovative solutions and cutting-edge technologies that enhance the efficiency and effectiveness of biotechnological applications. BNN offers a range of services, including data analysis, research consultancy, and access to proprietary databases that support academic institutions, pharmaceutical companies, and agricultural firms in their quest for scientific breakthroughs.

How the Company Makes Money

BNN generates revenue through multiple streams, including consultancy fees for research services provided to academic institutions and corporate clients, subscription fees for access to its proprietary databases and research findings, and licensing agreements for its patented technologies and products. Additionally, BNN collaborates with pharmaceutical companies and agricultural firms in joint research projects, which often include funding and investment from these partners. Strategic partnerships with universities and research institutions also contribute to funding through grants and collaborative projects, enhancing BNN's financial stability and growth potential.

B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview

Summary

B.R.A.I.N. Biotechnology Research and Information Network faces financial challenges, with persistent net losses and negative cash flows. While revenue growth indicates potential, profitability and liquidity remain concerns. The balance sheet shows improvement in debt management, but overall financial stability is a challenge.

Income Statement

The company shows a concerning trajectory with consistent net losses and declining profit margins. The TTM data indicates a negative EBIT and EBITDA, suggesting operational inefficiencies. Revenue has shown some growth over the years, but the net profit margin remains negative, indicating profitability challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, but recent TTM data suggests no total debt, indicating improvement in leverage. The equity ratio is low, reflecting potential risk. Historical stockholders' equity decline suggests financial instability.

Cash Flow

Operating cash flow is negative, indicating difficulties in generating cash from operations. Free cash flow remains negative, though recent financing activities have improved liquidity. The consistent negative free cash flow to net income ratio highlights ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.93M	54.63M	55.34M	49.51M	38.39M	38.23M
Gross Profit	29.94M	401.00K	3.47M	1.43M	-1.95M	21.20M
EBITDA	-2.06M	-4.23M	-1.98M	-1.30M	2.01M	-2.78M
Net Income	-11.70M	-11.13M	-8.28M	-6.59M	-4.97M	-9.68M
Balance Sheet
Total Assets	72.44M	88.74M	70.94M	77.99M	77.74M	72.15M
Cash, Cash Equivalents and Short-Term Investments	10.53M	27.29M	5.41M	8.53M	24.65M	19.05M
Total Debt	0.00	29.82M	25.32M	10.74M	2.64M	30.60M
Total Liabilities	66.27M	74.85M	47.92M	43.74M	35.91M	46.01M
Stockholders Equity	6.17M	12.62M	21.77M	29.64M	38.78M	20.79M
Cash Flow
Free Cash Flow	-9.26M	-5.31M	-6.86M	-7.57M	-5.17M	-7.63M
Operating Cash Flow	-7.70M	-3.58M	-4.22M	-1.49M	-3.91M	-4.77M
Investing Cash Flow	-918.00K	-1.69M	562.00K	-12.69M	-2.18M	-4.47M
Financing Cash Flow	6.14M	26.99M	459.00K	-1.97M	11.57M	13.09M

B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Positive. The current price of 3.12 is above the 20-day moving average (MA) of 2.72, above the 50-day MA of 2.40, and above the 200-day MA of 2.26, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 61.02 is Neutral, neither overbought nor oversold. The STOCH value of 38.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BNN.

B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GME	60 Neutral	€20.80M	11.72	8.35%	2.91%	-23.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNN	48 Neutral	€49.81M	-3.65	-111.86%	―	-4.90%	-69.80%
HPHA	39 Underperform	€137.55M	―	-112.95%	―	-64.15%	-39.31%